Home > Boards > US Listed > Biotechs > Bio-Path Holdings Inc. (BPTH)

Runnin, I expect the stock PPS will continue

Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
SJSTOCKSHARK Member Profile
 
Followed By 11
Posts 1,588
Boards Moderated 1
Alias Born 09/19/06
160x600 placeholder
Current Report Filing (8-k) Edgar (US Regulatory) - 11/15/2019 7:08:27 AM
Bio-Path Holdings Reports Third Quarter 2019 Financial Results GlobeNewswire Inc. - 11/15/2019 7:00:00 AM
Quarterly Report (10-q) Edgar (US Regulatory) - 11/14/2019 4:25:09 PM
Bio-Path Holdings to Announce Third Quarter 2019 Financial Results on November 15, 2019 GlobeNewswire Inc. - 11/8/2019 8:00:00 AM
Additional Proxy Soliciting Materials (definitive) (defa14a) Edgar (US Regulatory) - 11/1/2019 4:49:22 PM
Proxy Statement (definitive) (def 14a) Edgar (US Regulatory) - 11/1/2019 4:46:18 PM
Initial Statement of Beneficial Ownership (3) Edgar (US Regulatory) - 10/22/2019 5:06:33 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 10/15/2019 4:24:51 PM
Bio-Path Holdings Appoints Martina Molsbergen to Board of Directors GlobeNewswire Inc. - 10/15/2019 8:00:00 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 9/25/2019 5:17:26 PM
Bio-Path Updates Intellectual Property Portfolio with Addition of Recently Issued Second Platform Technology Patent GlobeNewswire Inc. - 9/25/2019 8:00:00 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 9/4/2019 4:07:11 PM
Bio-Path Holdings to Present at the H.C. Wainwright 21st Annual Global Investment Conference GlobeNewswire Inc. - 9/3/2019 4:01:00 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 8/27/2019 6:02:06 AM
Bio-Path Announces Patient Dosing in Amended Phase 2 Prexigebersen Trial in Acute Myeloid Leukemia GlobeNewswire Inc. - 8/26/2019 7:00:00 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 8/15/2019 7:06:51 AM
Bio-Path Holdings Reports Second Quarter 2019 Financial Results GlobeNewswire Inc. - 8/15/2019 7:00:00 AM
Quarterly Report (10-q) Edgar (US Regulatory) - 8/14/2019 4:20:01 PM
Bio-Path Holdings to Announce Second Quarter 2019 Financial Results on August 15, 2019 GlobeNewswire Inc. - 8/8/2019 4:01:00 PM
Prospectus Filed Pursuant to Rule 424(b)(5) (424b5) Edgar (US Regulatory) - 6/6/2019 5:07:29 PM
Prospectus Filed Pursuant to Rule 424(b)(5) (424b5) Edgar (US Regulatory) - 6/6/2019 5:05:06 PM
Notice of Effectiveness (effect) Edgar (US Regulatory) - 6/6/2019 6:01:49 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 6/4/2019 4:31:59 PM
Securities Registration Statement (simplified Form) (s-3) Edgar (US Regulatory) - 5/16/2019 4:19:14 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 5/16/2019 7:06:23 AM
SJSTOCKSHARK   Friday, 06/14/19 10:41:52 AM
Re: None
Post # of 6206 
Runnin, I expect the stock PPS will continue to decline once the Russell rebalance occurs. The time is now to raise funds.

The only catalyst for a sustained PPS move upwards is drug approval or a partnership. Neither of these will happen until the triple combination trial shows results. PN admitted it is tough for BPTH to recruit trial patients with the Venetoclax approval. We need enough for 3 to 5 years to complete trials. Selling 1 million shares to the Russell index funds secures the future. A million more shares in the float will have no effect on the company's value if one of their drugs works.

Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist